ArticleScientific reports2018
IL-33/ST2 signalling and crosstalk with FcεRI and TLR4 is targeted by the parasitic worm product, ES-62.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 196 citations in OpenAlex.
- The immune-modulatory potential of helminth-derived proteins in cellular models of inflammation: a systematic review with cross-study quantitative data analysis.Scientific reports · 2026Pooled it
- Curtailment of Toll-like receptor signalling and cytokine production in dendritic cells by secreted products of Heligmosomoides polygyrus.PLoS pathogens · 2026Article
- In Silico identification of inhalable small-molecule IL-33/ST2 antagonists for severe type-2-high asthma endotypes.Scientific reports · 2026Article
- Modulation of the Immune Response by Nematode Derived Molecules.International journal of molecular sciences · 2025Review
- Anti-Inflammatory Effects of Helminth-Derived Products: Potential Applications and Challenges in Diabetes Mellitus Management.Journal of inflammation research · 2024Review
- How to train your myeloid cells: a way forward for helminth vaccines?Frontiers in immunology · 2023Review
- The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers.International journal of molecular sciences · 2022Review
- Immunomodulators secreted from parasitic helminths act on pattern recognition receptors.Frontiers in parasitology · 2022Review
- Oxidation-Dependent Activation of Src Kinase Mediates Epithelial IL-33 Production and Signaling during Acute Airway Allergen Challenge.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Interference of LPSCells · 2021Article
- Responses of Mast Cells to Pathogens: Beneficial and Detrimental Roles.Frontiers in immunology · 2021Review
- Lipid profile of Trichinella papuae muscle-stage larvae.Scientific reports · 2020Article
- Beyond IgE: Alternative Mast Cell Activation Across Different Disease States.International journal of molecular sciences · 2020Review
- The IL-33/ST2 Axis in Immune Responses Against Parasitic Disease: Potential Therapeutic Applications.Frontiers in cellular and infection microbiology · 2020Review
- Review
- What Can Parasites Tell Us About the Pathogenesis and Treatment of Asthma and Allergic Diseases.Frontiers in immunology · 2020Review
- The IL-33/sST2 Axis in Thromboangiitis Obliterans.Journal of inflammation research · 2020Article
- IL33 and Mast Cells-The Key Regulators of Immune Responses in Gastrointestinal Cancers?Frontiers in immunology · 2020Review
- Modulation of Host Immunity by Helminths: The Expanding Repertoire of Parasite Effector Molecules.Immunity · 2018Review
- Interleukin-33: Its Emerging Role in Allergic Diseases.Molecules (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
ES-62 is a secreted parasitic worm-derived immunomodulator that exhibits therapeutic potential in allergy by downregulating aberrant MyD88 signalling to normalise the inflammatory phenotype and mast cell responses. IL-33 plays an important role in driving mast cell responses and promoting type-2 allergic inflammation, particularly with respect to asthma, via MyD88-integrated crosstalk amongst the IL-33 receptor (ST2), TLR4 and FcεRI. We have now investigated whether ES-62 targets this pathogenic network by subverting ST2-signalling, specifically by characterising how the functional outcomes of crosstalk amongst ST2, TLR4 and FcεRI are modulated by the worm product in wild type and ST2-deficient mast cells. This analysis showed that whilst ES-62 inhibits IL-33/ST2 signalling, the precise functional modulation observed varies with receptor usage and/or mast cell phenotype. Thus, whilst ES-62's harnessing of the capacity of ST2 to sequester MyD88 appears sufficient to mediate its inhibitory effects in peritoneal-derived serosal mast cells, downregulation of MyD88 expression appears to be required to dampen the higher levels of cytokine production typically released by bone marrow-derived mucosal mast cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.